Valuation: TaiRx, Inc.

Market Cap 1.49B 46.48M 40.64M 37.34M 34.81M 66.02M 4.43B 67.03M 448M 174M 2.18B 174M 171M 7.5B P/E 2024
-20.5x
P/E 2025 -11x
Enterprise Value 1.16B 36.15M 31.6M 29.04M 27.07M 51.34M 3.44B 52.12M 349M 136M 1.69B 136M 133M 5.83B EV / Sales 2024
286x
EV / Sales 2025 75.1x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day+0.76%
1 week-1.85%
Current month-1.49%
1 month-11.67%
3 months-12.25%
6 months-39.36%
Current year-39.50%
1 week 12.9
Extreme 12.9
13.55
1 month 12.9
Extreme 12.9
15.7
Current year 12.9
Extreme 12.9
23.45
1 year 12.9
Extreme 12.9
31.8
3 years 12.9
Extreme 12.9
44
5 years 12.9
Extreme 12.9
89.5
10 years 12.86
Extreme 12.86
89.5
Manager TitleAgeSince
Investor Relations Contact - -
Chief Executive Officer - 2011-08-21
Director of Finance/CFO - 2015-10-04
Director TitleAgeSince
Chairman - 2011-08-21
Director/Board Member - 2013-12-17
Director/Board Member - 2011-08-21
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%-1.85%-43.01%-60.68% 46.48M
+1.70%+7.41%+3.12%+8.46% 49.92B
+0.92%+3.93%+399.71%+605.33% 40.23B
+1.89%+8.32%+26.06%-6.35% 34.55B
+2.38%+6.35%+21.25%+64.58% 33.09B
+3.96%+10.67%+11.89%+38.86% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+133.27% 15.92B
+0.32%+0.58%+13.67%+19.09% 13.86B
+3.30%+0.76%+90.23%+99.12% 13.52B
Average +2.03%+5.09%+66.26%+100.19% 24.57B
Weighted average by Cap. +2.07%+6.53%+90.72%+137.70%

Financials

2024 2025
Net sales 8.22M 257K 225K 207K 193K 365K 24.5M 371K 2.48M 965K 12.04M 966K 945K 41.49M 27.88M 872K 762K 701K 653K 1.24M 83.05M 1.26M 8.41M 3.27M 40.82M 3.27M 3.2M 141M
Net income -139M -4.34M -3.8M -3.49M -3.25M -6.17M -414M -6.26M -41.9M -16.29M -203M -16.31M -15.96M -701M -221M -6.92M -6.05M -5.56M -5.18M -9.83M -659M -9.98M -66.73M -25.94M -324M -25.97M -25.41M -1.12B
Net Debt -505M -15.8M -13.81M -12.69M -11.83M -22.44M -1.5B -22.78M -152M -59.23M -739M -59.3M -58.02M -2.55B -330M -10.34M -9.04M -8.31M -7.74M -14.68M -984M -14.91M -99.71M -38.76M -484M -38.81M -37.97M -1.67B
Logo TaiRx, Inc.
TaiRx Inc is a Taiwan-based company mainly engaged in the development and research of new drugs. The Company primarily focus on the research and development of cancer treatment drugs and sepsis adjuvant therapy drugs. The Company's main products include CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, TRX-105 and others. CVM-1118 and Rexis are in clinical trials, and Zelnite drugs are sold to domestic medical institutions at all levels through distributors.
Employees
-
Date Price Change Volume
26-07-03 NT$13.25 +0.76% 60,270
26-07-02 NT$13.15 -2.23% 42,472
26-07-01 NT$13.45 0.00% 56,946
26-06-30 NT$13.45 0.00% 46,230
26-06-29 NT$13.45 -0.37% 66,955
  1. Stock Market
  2. Stocks
  3. 6580 Stock